Cellectar Biosciences (CLRB) to Post Earnings on Thursday

Cellectar Biosciences (NASDAQ:CLRB) is anticipated to post its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Cellectar Biosciences to announce earnings of ($0.55) per share and revenue of $12.00 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:30 AM ET.

Cellectar Biosciences (NASDAQ:CLRB) last posted its quarterly earnings results on Thursday, May 14th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.88) by $0.55. On average, analysts expect Cellectar Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Cellectar Biosciences Stock Performance

Shares of Cellectar Biosciences stock opened at $2.60 on Tuesday. The stock has a market capitalization of $20.77 million, a PE ratio of -0.39 and a beta of 0.55. Cellectar Biosciences has a 52 week low of $2.20 and a 52 week high of $6.52. The stock has a 50 day moving average price of $2.57 and a two-hundred day moving average price of $2.89.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. LADENBURG THALM/SH SH started coverage on shares of Cellectar Biosciences in a research report on Friday, May 15th. They issued a “buy” rating for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cellectar Biosciences in a report on Friday, July 17th. Roth Capital reissued a “buy” rating and set a $11.00 target price on shares of Cellectar Biosciences in a research report on Tuesday, May 5th. Wall Street Zen upgraded shares of Cellectar Biosciences to a “hold” rating in a report on Saturday, June 20th. Finally, Brookline Capital Markets raised shares of Cellectar Biosciences to a “strong-buy” rating in a research report on Sunday, July 12th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $11.00.

Institutional Trading of Cellectar Biosciences

A number of large investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new position in shares of Cellectar Biosciences during the 4th quarter worth $36,000. Bank of America Corp DE increased its stake in shares of Cellectar Biosciences by 25.3% in the fourth quarter. Bank of America Corp DE now owns 206,783 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 41,704 shares in the last quarter. Dimensional Fund Advisors LP bought a new stake in shares of Cellectar Biosciences in the third quarter valued at approximately $73,000. Geode Capital Management LLC raised its position in shares of Cellectar Biosciences by 15.0% in the fourth quarter. Geode Capital Management LLC now owns 28,636 shares of the biopharmaceutical company’s stock valued at $84,000 after purchasing an additional 3,744 shares during the period. Finally, Citadel Advisors LLC purchased a new stake in shares of Cellectar Biosciences during the 3rd quarter valued at approximately $104,000. Hedge funds and other institutional investors own 16.41% of the company’s stock.

About Cellectar Biosciences

Cellectar Biosciences, Inc is a clinical?stage biopharmaceutical company focused on the development of targeted cancer therapies and imaging agents. The company’s proprietary phospholipid drug conjugate (PDC) technology platform is designed to selectively deliver therapeutic and diagnostic payloads to malignant cells while sparing healthy tissue. Through its PDC approach, Cellectar aims to improve the efficacy and safety profile of traditional treatments like chemotherapy and radiotherapy.

Its lead therapeutic candidate, CLR 131, is a radioisotope?labeled PDC being evaluated in Phase II clinical trials for relapsed or refractory B?cell malignancies, including multiple myeloma and non?Hodgkin lymphoma.